Coding Polymorphisms in CD33 and Response to Gemtuzumab Ozogamicin in Pediatric Patients With AML: A Pilot Study

Leukemia - United Kingdom
doi 10.1038/leu.2008.185
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Gemtuzumab Ozogamicin Makes a Comeback

Cancer Discovery
Oncology
2017English

High CD33-antigen Loads in Peripheral Blood Limit the Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) Treatment in Acute Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2004English

Preliminary Results of the Safety of Immunotherapy With Gemtuzumab Ozogamicin Following Reduced Intensity Allogeneic Stem Cell Transplant in Children With CD33+ Acute Myeloid Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2005English

Antibody-Based Therapy of Acute Myeloid Leukemia With Gemtuzumab Ozogamicin

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Patients With Prior Gemtuzumab Ozogamicin: Literature Analysis of Survival After Defibrotide Treatment

Blood Cancer Journal
OncologyHematology
2020English

High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research
Cancer ResearchOncologyHematology
2011English

Gemtuzumab Ozogamicin in Children With Relapsed or Refractory Acute Myeloid Leukemia: A Report of Berlin-Frankfurt-Münster Study Group

Haematologica
Hematology
2018English

Reinduction Chemotherapy With Gemtuzumab Ozogamicin and Intermediate/High-Dose Cytarabine: A Single-Center Experience

Open Journal of Blood Diseases
2014English

Gene Expression in Response to Exercise in Patients With Chronic Fatigue Syndrome: A Pilot Study

Frontiers in Physiology
Physiology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy